Utah is currently home to 1240 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Salt Lake City, Murray, Ogden and West Jordan. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS)
NCT05895552
Recruiting
This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and PK of RTA 901 in qualified subjects with DPNP. Each study part will be randomized into 3 treatment arms; 2 different doses of RTA 901 and a Placebo. The doses of RTA 901 in Part 2 will be selected based on the Exposure-Response (E-R) analyses of data from Part 1. A total of 384 subjects will be randomized in this study. Each part will have 192 subjects, with 64 subjec... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Velocity Clinical Research, Salt Lake City, West Jordan, Utah
Conditions: Diabetic Peripheral Neuropathic Pain
Register for Updates
Mindfulness Intervention in Orthopedic Trauma Patients
NCT05634278
Recruiting
This project a single-site 3-arm parallel group randomized clinical trial conducted at a tertiary level 1 trauma center among patients undergoing operative fixation of a lower extremity fracture.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/31/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Pain, Anxiety
Register for Updates
A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifan Monotherapy in Participants With Advanced Renal Cell Carcinoma (MK-6482-024/LITESPARK-024)
NCT05468697
Recruiting
The purpose of this study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: Huntsman Cancer Institute-HCI Clinical Trials Office ( Site 1004), Salt Lake City, Utah
Conditions: Renal Cell Carcinoma
Register for Updates
The Acute Burn ResUscitation Multicenter Prospective Trial
NCT04356859
Recruiting
This is a prospective randomized multi-center study which will compare acute fluid resuscitation using a colloid strategy (LR + 5% Albumin) to a crystalloid strategy (LR alone), in adults with an acute burn involving at least 25% of their total body surface area.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/31/2024
Locations: University of Utah Health, Salt Lake City, Utah
Conditions: Burn Injury
Register for Updates
A Randomized Multicenter Study for Isolated Skin Vasculitis
NCT02939573
Recruiting
Multi-center sequential multiple assignment randomized trial comparing the effectiveness of three different standard of care treatment options for patients with isolated skin vasculitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/30/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Primary Cutaneous Vasculitis, Cutaneous Polyarteritis Nodosa, IgA Vasculitis, Henoch-Schönlein Purpura
Register for Updates
Smoldering Myeloma High-Risk Patient Observation and Longitudinal Insight Trial
NCT06212323
Recruiting
The purpose of this study is to define the natural history of high-risk smoldering myeloma in a modern cohort of patients undergoing close standard of care follow-up with diffusion weighted whole body magnetic resonance imaging.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah
Conditions: Smoldering Multiple Myeloma
Register for Updates
A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis
NCT05757856
Recruiting
An open-label phase 1b study to assess the safety and exploratory diagnostic performance of the oral radiopharmaceutical agent NDX-3315 and NDX-3324 in healthy participants and patients with eosinophilic esophagitis (EoE).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
01/29/2024
Locations: University of Utah, Salt Lake City, Utah
Conditions: Eosinophilic Esophagitis
Register for Updates
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
NCT03504488
Recruiting
The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: University of Utah - Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Non Small Cell Lung Cancer, Triple Negative Breast Cancer, Melanoma, Head and Neck Cancer
Register for Updates
Human Epilepsy Project 3
NCT05374928
Recruiting
By carrying a careful, large-scale and ambitious prospective study of a cohort of participants with generalized epilepsy, the study team hopes to clarify the likelihood of response and remission in this type of epilepsy, and try to explore the underlying biological drivers of treatment response, including novel realms of exploration such as impact of the microbiome, and genetics. The identification of biomarkers that predict the likelihood of disease response would allow epilepsy patients to mak... Read More
Gender:
All
Ages:
13 years and above
Trial Updated:
01/24/2024
Locations: University of Utah Hospital, Salt Lake City, Utah
Conditions: Idiopathic Generalized Epilepsy
Register for Updates
Ca-Mg Butyrate in GWI
NCT05367245
Recruiting
The primary objective of this clinical trial is to determine if treatment with Butyrate formulation that consists of butyric acid as calcium and magnesium derivatives (Ca-Mg Butyrate) improves the physical function of men and women Veterans suffering from Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short Form Health Survey 36-item (VSF-36), with respect to physical functioning and symptoms. The secondary outcome will focus on the drug's role in (a) restor... Read More
Gender:
All
Ages:
Between 40 years and 70 years
Trial Updated:
01/24/2024
Locations: VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City, Utah
Conditions: Gulf War Illness, Chronic Fatigue, Neurocognitive Dysfunction
Register for Updates
Validation of Early Prognostic Data for Recovery Outcome After Stroke for Future, Higher Yield Trials
NCT05338697
Recruiting
VERIFY will validate biomarkers of upper extremity (UE) motor outcome in the acute ischemic stroke window for immediate use in clinical trials, and explore these biomarkers in acute intracerebral hemorrhage. VERIFY will create the first multicenter, large-scale, prospective dataset of clinical, transmagnetic stimulation (TMS), and MRI measures in the acute stroke time window.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: University of Utah Healthcare, Salt Lake City, Utah
Conditions: Stroke, Stroke, Acute, Stroke, Ischemic, Stroke Hemorrhagic
Register for Updates
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
NCT04849728
Recruiting
This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3
Gender:
All
Ages:
18 years and above
Trial Updated:
01/24/2024
Locations: Lone Peak Family Health, Draper, Utah
Conditions: NASH - Nonalcoholic Steatohepatitis
Register for Updates